ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
February 16 2024 - 9:30AM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically proven and
practical products that improve the health and productivity of
dairy and beef cattle, expects to report unaudited financial
results for the quarter and year ended December 31, 2023 after the
market closes on Tuesday, February 27, 2024.
The Company has scheduled a conference call the next morning,
Wednesday, February 28, 2024, at 9:00 AM ET to review its 2023
unaudited financial results. This date has been pushed back six
days from the original date first announced on January 8, 2024.
Interested parties can access the conference call by dialing (844)
855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM
ET. A teleconference replay of the call will be available until
March 6, 2024 at (877) 344-7529 (toll free) or (412) 317-0088
(international), utilizing replay access code #2442952.
The Company anticipates no change to the preliminary sales
results for the fourth quarter and year ended December 31, 2023
that were disclosed on January 8, 2024. The Company expects to file
its Annual Report on Form 10-K around the end of March 2024.
Investors are encouraged to review the Company’s updated
Corporate Presentation slide deck that provides an overview of the
Company’s business which can be accessed under the “Investors” tab
of the Company’s website at www.immucell.com, or by request to the
Company. An updated version of the slide deck will be made
available under the “Investors” tab of the Company’s website after
the market closes on Tuesday, February 27, 2024 (which date is six
days later than originally announced on January 8, 2024).
About ImmuCell:ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and
productivity of dairy and beef calves. ImmuCell manufactures
and markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain®, a novel treatment for subclinical
mastitis in dairy cows with a no milk discard claim that provides
an alternative to traditional antibiotics. Press releases and other
information about the Company are available at:
http://www.immucell.com.
Contacts: |
|
Michael F. Brigham, President and CEOImmuCell Corporation (207)
878-2770Joe Diaz, Robert Blum and Joe DorameLytham Partners,
LLC(602) 889-9700 iccc@lythampartners.com |
|
|
|
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2024 to May 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From May 2023 to May 2024